Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-BEP vs BEP in Intermediate Prognosis Germ Cell Cancer
NCT00003643Phase 3Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 1998
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in Germ cell cancer (GCT) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Failure-free survival at 3 years. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
Germ cell cancer (GCT)
Beyond the preview
Go deeper on NCT00003643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003643.